COVID-19 drug trial halted: ABX464 fails to prevent respiratory failure in At-Risk patients
NCT ID NCT04393038
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This study tested an experimental drug called ABX464 in 509 older adults (65+) and younger people with risk factors like obesity or diabetes who had COVID-19. The goal was to see if the drug could reduce inflammation and prevent severe breathing problems that require a breathing machine. The study was stopped early because the drug did not show enough benefit compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Asklepios Klinik Altona
Hamburg, 22763, Germany
-
Asklepios Klinik St. Georg
Hamburg, 20099, Germany
-
Centre Hospitalier Départemental de Vendée
La Roche-sur-Yon, 85000, France
-
Centre Hospitalier Universitaire de Nice
Nice, 06003, France
-
Centre hospitalier Saint Pierre
Brussels, 1000, Belgium
-
Centro Oncológico de Roraima - CECOR - NAP
Boa Vista, Roraima, 69310-000, Brazil
-
Centro de Prevención y Rehabilitación de Enfermedades Pulmon
Nuevo León, 64460, Mexico
-
Conjunto Hospitalar do Mandaqui
São Paulo, 02401-400, Brazil
-
Consultorio médico
Mérida, Yucatán, 97070, Mexico
-
Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico - Infectious Diseases
Milan, Lombardy, 20122, Italy
-
Fundacao de Medicina Tropical Doutor Heitor Vieira Dourado - Instituto de Pesquisa Clínica Carlos Borborema
Manaus, Amazonas, 69040-000, Brazil
-
H.G.U. Alicante
Alicante, 03010, Spain
-
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
Hospital Universitario Infanta Leonor
Madrid, 28031, Spain
-
Hospital das Clinicas da FMUSP
São Paulo, São Paulo, 05403-000, Brazil
-
Hospital de La Princesa
Madrid, 28006, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Hôpital Erasme
Brussels, 1070, Belgium
-
Hôpital Nord
Amiens, 80000, France
-
Hôpital Saint-Antoine
Paris, 75571, France
-
Instituto Nacional de Infectologia Evandro Chagas - FIOCRUZ Rio de Janeiro
Rio de Janeiro, 21040-360, Brazil
-
Ospedale A. Manzonidi Lecco - ASST Lecco
Lecco, 23900, Italy
-
Ospedale Luigi Sacco, AO-PU
Milan, Lombardy, 20157, Italy
-
Ospedale Niguarda
Milan, 20162, Italy
-
Ospedale San Paolo
Milan, Lombardy, 20142, Italy
-
Ospedale di Vittorio Veneto - Medecina generale
Vittorio Veneto, Treviso, 31029, Italy
-
Royal Free Hospital
London, NW3 2QG, United Kingdom
-
UZ Gent
Ghent, 9000, Belgium
-
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, 53127, Germany
-
Universitätsmedizin Mannheim Ruprecht-Karls-Universität Heid
Mannheim, Baden-Wurttemberg, 68167, Germany
Conditions
Explore the condition pages connected to this study.